,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,trailingPE,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,2 University Plaza,Suite 100,Hackensack,NJ,07601,United States,201 696 9345,https://www.protalix.com,Biotechnology,Healthcare,"Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.",193,"{'maxAge': 1, 'name': 'Mr. Dror  Bashan', 'age': 55, 'title': 'Pres, CEO & Director', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 473156, 'exercisedValue': 0, 'unexercisedValue': 15938}",1672444800,86400,4,1.73,1.73,1.72,1.78,1.73,1.73,1.72,1.78,0.0,1.326417,59.0,7.695652,1288756,1288756,924900,519530,519530,1.73,1.77,2900,1400,126698016,1.0,3.55,1.8780371,1.8182,1.9004,0.0,0.0,USD,101619720,0.13194,63586622,71580800,5707603,5389380,1690761600,1693440000,0.0797,0.09548,0.066939995,6.65,0.08189999,0.545,3.2477062,1672444800,1703980800,1688083200,8901000,0.03,0.23,0.69,1:10,1576800000,1.506,7.548,ASE,EQUITY,PLX,PLX,"Protalix BioTherapeutics, Inc. ","Protalix BioTherapeutics, Inc.",895239000,America/New_York,EDT,-14400000,1.77,16.0,16.0,16.0,16.0,2.0,buy,1,48184000,0.673,13463000,25969000,2.26,3.184,67463000,66.585,1.197,0.1035,0.6115,28046000,-4095250,-9840000,3.007,0.72275,0.19955999,0.18294,USD,
1,2 University Plaza,Suite 100,Hackensack,NJ,07601,United States,201 696 9345,https://www.protalix.com,Biotechnology,Healthcare,"Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.",193,"{'maxAge': 1, 'name': 'Mr. Eyal  Rubin M.B.A.', 'age': 46, 'title': 'Sr. VP, CFO, Treasurer & Corp. Sec.', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 813725, 'exercisedValue': 0, 'unexercisedValue': 7438}",1672444800,86400,4,1.73,1.73,1.72,1.78,1.73,1.73,1.72,1.78,0.0,1.326417,59.0,7.695652,1288756,1288756,924900,519530,519530,1.73,1.77,2900,1400,126698016,1.0,3.55,1.8780371,1.8182,1.9004,0.0,0.0,USD,101619720,0.13194,63586622,71580800,5707603,5389380,1690761600,1693440000,0.0797,0.09548,0.066939995,6.65,0.08189999,0.545,3.2477062,1672444800,1703980800,1688083200,8901000,0.03,0.23,0.69,1:10,1576800000,1.506,7.548,ASE,EQUITY,PLX,PLX,"Protalix BioTherapeutics, Inc. ","Protalix BioTherapeutics, Inc.",895239000,America/New_York,EDT,-14400000,1.77,16.0,16.0,16.0,16.0,2.0,buy,1,48184000,0.673,13463000,25969000,2.26,3.184,67463000,66.585,1.197,0.1035,0.6115,28046000,-4095250,-9840000,3.007,0.72275,0.19955999,0.18294,USD,
2,2 University Plaza,Suite 100,Hackensack,NJ,07601,United States,201 696 9345,https://www.protalix.com,Biotechnology,Healthcare,"Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.",193,"{'maxAge': 1, 'name': 'Mr. Yaron  Naos', 'age': 58, 'title': 'Sr. VP of Operations', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 409955, 'exercisedValue': 0, 'unexercisedValue': 7225}",1672444800,86400,4,1.73,1.73,1.72,1.78,1.73,1.73,1.72,1.78,0.0,1.326417,59.0,7.695652,1288756,1288756,924900,519530,519530,1.73,1.77,2900,1400,126698016,1.0,3.55,1.8780371,1.8182,1.9004,0.0,0.0,USD,101619720,0.13194,63586622,71580800,5707603,5389380,1690761600,1693440000,0.0797,0.09548,0.066939995,6.65,0.08189999,0.545,3.2477062,1672444800,1703980800,1688083200,8901000,0.03,0.23,0.69,1:10,1576800000,1.506,7.548,ASE,EQUITY,PLX,PLX,"Protalix BioTherapeutics, Inc. ","Protalix BioTherapeutics, Inc.",895239000,America/New_York,EDT,-14400000,1.77,16.0,16.0,16.0,16.0,2.0,buy,1,48184000,0.673,13463000,25969000,2.26,3.184,67463000,66.585,1.197,0.1035,0.6115,28046000,-4095250,-9840000,3.007,0.72275,0.19955999,0.18294,USD,
3,2 University Plaza,Suite 100,Hackensack,NJ,07601,United States,201 696 9345,https://www.protalix.com,Biotechnology,Healthcare,"Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.",193,"{'maxAge': 1, 'name': 'Ms. Yael  Fellous', 'title': 'VP of HR', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.73,1.73,1.72,1.78,1.73,1.73,1.72,1.78,0.0,1.326417,59.0,7.695652,1288756,1288756,924900,519530,519530,1.73,1.77,2900,1400,126698016,1.0,3.55,1.8780371,1.8182,1.9004,0.0,0.0,USD,101619720,0.13194,63586622,71580800,5707603,5389380,1690761600,1693440000,0.0797,0.09548,0.066939995,6.65,0.08189999,0.545,3.2477062,1672444800,1703980800,1688083200,8901000,0.03,0.23,0.69,1:10,1576800000,1.506,7.548,ASE,EQUITY,PLX,PLX,"Protalix BioTherapeutics, Inc. ","Protalix BioTherapeutics, Inc.",895239000,America/New_York,EDT,-14400000,1.77,16.0,16.0,16.0,16.0,2.0,buy,1,48184000,0.673,13463000,25969000,2.26,3.184,67463000,66.585,1.197,0.1035,0.6115,28046000,-4095250,-9840000,3.007,0.72275,0.19955999,0.18294,USD,
